X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA BIOCON LTD NATCO PHARMA/
BIOCON LTD
 
P/E (TTM) x 24.1 80.0 30.1% View Chart
P/BV x 18.3 7.5 242.5% View Chart
Dividend Yield % 0.6 0.2 380.6%  

Financials

 NATCO PHARMA   BIOCON LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
BIOCON LTD
Mar-17
NATCO PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs8771,162 75.5%   
Low Rs424483 87.8%   
Sales per share (Unadj.) Rs223.4194.6 114.8%  
Earnings per share (Unadj.) Rs31.134.4 90.3%  
Cash flow per share (Unadj.) Rs40.348.3 83.4%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.1 632.2%  
Book value per share (Unadj.) Rs219.5241.9 90.7%  
Shares outstanding (eoy) m33.07200.00 16.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.2 68.9%   
Avg P/E ratio x20.923.9 87.6%  
P/CF ratio (eoy) x16.117.0 94.8%  
Price / Book Value ratio x3.03.4 87.2%  
Dividend payout %16.12.9 553.7%   
Avg Mkt Cap Rs m21,504164,440 13.1%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m1,1287,470 15.1%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m7,38938,911 19.0%  
Other income Rs m1671,571 10.6%   
Total revenues Rs m7,55640,482 18.7%   
Gross profit Rs m1,7939,795 18.3%  
Depreciation Rs m3042,772 11.0%   
Interest Rs m366260 140.8%   
Profit before tax Rs m1,2908,334 15.5%   
Minority Interest Rs m46163 28.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,616 19.1%   
Profit after tax Rs m1,0276,881 14.9%  
Gross profit margin %24.325.2 96.4%  
Effective tax rate %23.919.4 123.4%   
Net profit margin %13.917.7 78.6%  
BALANCE SHEET DATA
Current assets Rs m3,68140,477 9.1%   
Current liabilities Rs m3,12316,783 18.6%   
Net working cap to sales %7.660.9 12.4%  
Current ratio x1.22.4 48.9%  
Inventory Days Days8960 150.1%  
Debtors Days Days5983 70.8%  
Net fixed assets Rs m7,68545,073 17.1%   
Share capital Rs m3311,000 33.1%   
"Free" reserves Rs m6,67047,377 14.1%   
Net worth Rs m7,25948,377 15.0%   
Long term debt Rs m95521,082 4.5%   
Total assets Rs m11,95793,942 12.7%  
Interest coverage x4.533.1 13.7%   
Debt to equity ratio x0.10.4 30.2%  
Sales to assets ratio x0.60.4 149.2%   
Return on assets %11.77.6 153.3%  
Return on equity %14.214.2 99.5%  
Return on capital %20.712.6 164.4%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44512,988 26.5%   
Fx outflow Rs m7037,899 8.9%   
Net fx Rs m2,7435,089 53.9%   
CASH FLOW
From Operations Rs m1,4406,400 22.5%  
From Investments Rs m-1,089-4,985 21.8%  
From Financial Activity Rs m-353-1,775 19.9%  
Net Cashflow Rs m-1-473 0.3%  

Share Holding

Indian Promoters % 52.0 40.4 128.8%  
Foreign collaborators % 1.5 20.6 7.1%  
Indian inst/Mut Fund % 7.8 8.4 93.3%  
FIIs % 16.6 10.7 155.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.9 130.7%  
Shareholders   25,395 109,995 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS